Sales of the global pharmaceutical industry increased

Although sales of the top ten pharmaceutical companies in the world increased by 13% between 2009 and 2010, their profits have dropped by 4% to about 34 billion Euros. Roland Berger experts believe that this is due to the characteristics of mature markets.

“Price pressures have increased, regulations in the health care system have changed, and new drugs have been subject to stricter approval procedures. The pharmaceutical markets in Europe and the United States are falling into stagnation,” said Roland Berger, partner Martin. Erhart explained, “But in emerging markets we have seen a strong growth momentum. Even so, profits have decreased, and to a large extent from non-patented products.”

The report said that in the coming years, high-growth emerging markets will be the main force driving the growth of the global pharmaceutical market. By 2016, the average annual growth rate of the international pharmaceutical product market will reach 4.5%, of which the emerging market will be close to 12%. In particular, the pharmaceutical market growth in China, Brazil, India and Russia will far exceed the average value. According to experts from Roland Berger, overall, by 2016, the market share of emerging markets in the global pharmaceutical industry will reach about 40%.

"The growing purchasing power in emerging markets, the growing number of middle-class people, and the increasingly healthy medical insurance system have greatly increased medical demand," said Roland Berger, partner and author of this report. Hosseini said.